Supernus Pharmaceuticals (SUPN) Stock News
$SUPN · NASDAQ · HEALTHCARE · 2 stories in 30 daysBORSA has published 2 stories on Supernus Pharmaceuticals (SUPN) in the past 30 days. BORSA’s news read on SUPN is bearish at 35/100, unchanged over 24 hours, based on 2 company events over the past 7 days. SUPN last closed at $41.92 on Oct 30, up 3.00% over five sessions and down 0.62% over the past month. Supernus Pharmaceuticals last reported quarterly results on Aug 3, 2026, for the quarter ended Jun 30, 2026.
The wire on $SUPN
newest first · updated · direct subject stories onlySupernus Pharmaceuticals halted by NASDAQ pending additional information.
neutral 50 · impact 30S&P Dow Jones Indices revised the effective date for Huron Consulting Group (HURN) to enter the S&P SmallCap 600 to Tuesday, November 3, instead of November 2. Huron replaces Supernus Pharmaceuticals (SUPN), which is being acquired by Indivior Pharmaceuticals (INDV). Post-merger, Indivior will assume the name Supernus Inc. and trade under SUPN, remaining in the index.
· impact 40